中外医疗
中外醫療
중외의료
China Foreign Medical Treatment
2015年
28期
116-118
,共3页
血清异常凝血酶原%肝癌%诊断价值%意义
血清異常凝血酶原%肝癌%診斷價值%意義
혈청이상응혈매원%간암%진단개치%의의
Abnormal serum prothrombin%Liver cancer%Diagnostic value%Meaning
目的 探讨血清异常凝血酶原检测在肝癌患者中的诊断价值及其意义. 方法 随机选取2012年4月—2014年4月该院收治的100例原发性肝癌患者资料进行分析,将其设置为实验组,同期选择100例非原发性肝癌患者作为对照组,入选患者均检测血清异常凝血酶原, 分析血清异常凝血酶原检测在肝癌患者中的检测效果. 结果 实验组原发性肝癌患者AFP指标,血清异常凝血酶原指标,显著高于对照组其他疾病患者(P<0.05);慢性肝病、消化道肿瘤、继发性肝癌以及其他肝脏疾病患者相比血清AFP和血清异常凝血酶原显著低于对照组(P<0.05);血清异常凝血酶原诊断符合率、阳性预测值、阴性预测值,显著高于单一甲胎蛋白检测(P<0.05);血清异常凝血酶原联合甲胎蛋白检测特异性、符合率、阳性预测值,显著高于甲胎蛋白和血清异常凝血酶原(P<0.05). 结论 肝癌患者治疗过程中检测血清异常凝血酶原效果理想,且检测过程中联合甲胎蛋白能够提高患者敏感性和特异性.
目的 探討血清異常凝血酶原檢測在肝癌患者中的診斷價值及其意義. 方法 隨機選取2012年4月—2014年4月該院收治的100例原髮性肝癌患者資料進行分析,將其設置為實驗組,同期選擇100例非原髮性肝癌患者作為對照組,入選患者均檢測血清異常凝血酶原, 分析血清異常凝血酶原檢測在肝癌患者中的檢測效果. 結果 實驗組原髮性肝癌患者AFP指標,血清異常凝血酶原指標,顯著高于對照組其他疾病患者(P<0.05);慢性肝病、消化道腫瘤、繼髮性肝癌以及其他肝髒疾病患者相比血清AFP和血清異常凝血酶原顯著低于對照組(P<0.05);血清異常凝血酶原診斷符閤率、暘性預測值、陰性預測值,顯著高于單一甲胎蛋白檢測(P<0.05);血清異常凝血酶原聯閤甲胎蛋白檢測特異性、符閤率、暘性預測值,顯著高于甲胎蛋白和血清異常凝血酶原(P<0.05). 結論 肝癌患者治療過程中檢測血清異常凝血酶原效果理想,且檢測過程中聯閤甲胎蛋白能夠提高患者敏感性和特異性.
목적 탐토혈청이상응혈매원검측재간암환자중적진단개치급기의의. 방법 수궤선취2012년4월—2014년4월해원수치적100례원발성간암환자자료진행분석,장기설치위실험조,동기선택100례비원발성간암환자작위대조조,입선환자균검측혈청이상응혈매원, 분석혈청이상응혈매원검측재간암환자중적검측효과. 결과 실험조원발성간암환자AFP지표,혈청이상응혈매원지표,현저고우대조조기타질병환자(P<0.05);만성간병、소화도종류、계발성간암이급기타간장질병환자상비혈청AFP화혈청이상응혈매원현저저우대조조(P<0.05);혈청이상응혈매원진단부합솔、양성예측치、음성예측치,현저고우단일갑태단백검측(P<0.05);혈청이상응혈매원연합갑태단백검측특이성、부합솔、양성예측치,현저고우갑태단백화혈청이상응혈매원(P<0.05). 결론 간암환자치료과정중검측혈청이상응혈매원효과이상,차검측과정중연합갑태단백능구제고환자민감성화특이성.
Objective To evaluate the clinical value and significance of serum abnormal prothrombin in diagnosis of patients with liver cancer. Methods 100 patients with primary liver cancer admitted to our hospital between April 2012 and April 2014 were in-cluded in the study and were assigned to the experimental group, and other 100 patients with non-primary liver cancer were as-signed to the control group. Detection of serum abnormal prothrombin was performed on all the patients included to determine its diagnostic effect. Results The AFP and serum abnormal prothrombin levels were all significantly higher in the experimental group than in the control group (P<0.05); The AFP and serum abnormal prothrombin levels were significantly lower in patients with chronic liver disease, digestive tract cancer and other liver diseases than those in the control group (P<0.05); diagnostic accuracy, positive predictive value and negative predictive value were of serum abnormal prothrombin were significantly higher than those of Alpha-fetoprotein (P<0.05); diagnostic accuracy, positive predictive value and negative predictive value of serum abnormal pro-thrombin in combination with Alpha-fetoprotein were significantly higher than those of serum abnormal prothrombin and Alpha-fe-toprotein alone (P<0.05). Conclusion Serum abnormal prothrombin in clinical diagnosis of patients with liver cancer can bring ideal effect, and it combined with Alpha-fetoprotein can improve the sensitivity and specificity of the detection.
